Replies to post #39615 on Cel Sci Corporation (CVM)

[Biobonic]

Expanding role of the medical oncologist in the management of head and neck cancer CA Cancer J Clin. Jan-Feb 2008

Quote:
The multidisciplinary approach to treating squamous cell carcinoma of the head and neck is complex and evolving. This article aims to review some recent developments in squamous cell carcinoma of the head and neck, in particular the expanding role of chemotherapy in its management. Surgery and radiotherapy have remained the mainstay of therapy. Chemotherapy is increasingly being incorporated into the treatment of squamous cell carcinoma of the head and neck


Eur J Cancer. 2010 Jul
Quote:
The treatment of locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) has evolved in recent years as a consequence of a better understanding of the potential benefits associated with altered radiation fractionation regimens, concurrently administered chemotherapy and radiotherapy (chemoradiotherapy) and induction chemotherapy. Concurrent chemoradiotherapy is a treatment option for technically resectable disease, where functional morbidity precludes the use of surgery. Induction chemotherapy followed by radiotherapy may also be used in this setting, and has been validated for larynx preservation.


I can cut and paste...

Comprehend...naaa..

[W_W]

When 298 events were reached, not everyone was at 5 year or beyond. So the group size is smaller. The number of death in low risk group is smaller. the high risk group number therefore will be larger than you thought.